OTCM
TLIS
Market cap2mUSD
Apr 21, Last price
1.60USD
Name
Talis Biomedical Corp
Chart & Performance
P/E
—
P/S
7.08
EPS
—
Div Yield, %
—
Shrs. gr., 5y
64.60%
Rev. gr., 5y
-29.64%
Revenues
412k
-88.72%
Net income
-62m
L-44.08%
CFO
-53m
L-46.83%
Earnings
May 06, 2025
Profile
Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 412 -88.72% | 3,652 | ||||
Cost of revenue | 40,735 | 79,222 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (40,323) | (75,570) | ||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | (40,323) | (75,570) | ||||
Net income | (62,007) -44.08% | (110,885) -41.78% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 33 | 406 | ||||
BB yield | -0.24% | -3.42% | ||||
| Debt | ||||||
Debt current | 5,764 | 3,703 | ||||
Long-term debt | 36,454 | 63,461 | ||||
Deferred revenue | ||||||
Other long-term liabilities | (7,469) | |||||
Net debt | (36,056) | (64,803) | ||||
| Cash flow | ||||||
Cash from operating activities | (53,240) | (100,136) | ||||
CAPEX | (486) | (1,615) | ||||
Cash from investing activities | (486) | (1,615) | ||||
Cash from financing activities | 33 | 406 | ||||
FCF | (21,540) | (86,367) | ||||
| Balance | ||||||
Cash | 76,732 | 130,191 | ||||
Long term investments | 1,542 | 1,776 | ||||
Excess cash | 78,253 | 131,784 | ||||
Stockholders' equity | (539,958) | (477,948) | ||||
Invested Capital | 631,624 | 630,800 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 1,818 | 1,776 | ||||
Price | 7.45 11.44% | 6.69 -88.89% | ||||
Market cap | 13,540 14.07% | 11,870 -86.93% | ||||
EV | (22,513) | (52,930) | ||||
EBITDA | (39,553) | (66,740) | ||||
EV/EBITDA | 0.57 | 0.79 | ||||
Interest | 2,127 | |||||
Interest/NOPBT | ||||||